Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Bhumi Amla (Phyllanthus niruri) is an Ayurvedic herb rich in lignans like phyllanthin and hypophyllanthin, contributing to its hepatoprotective and nephroprotective actions. It primarily modulates enzyme systems and inhibits crystal formation, supporting liver health and kidney stone management.
Origin & History
Bhumi Amla (Phyllanthus niruri), also known as 'Stone Breaker,' is a small annual herbaceous plant (50-70 cm tall) native to tropical and subtropical regions worldwide, belonging to the Euphorbiaceae family. The whole plant is harvested and processed into powder, juice, or extracts through drying and grinding or solvent extraction methods. Commercial preparations are often standardized to contain 20% tannins.
Research Narrative (Provisional)
The available research dossier lacks specific human clinical trials, RCTs, or meta-analyses with PubMed PMIDs. While sources mention hepatoprotective, antioxidant, antiviral, hypoglycemic, and anti-inflammatory properties, these are based on traditional use and preliminary phytochemical research rather than controlled human studies.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Bhumi Amla (Phyllanthus niruri) is a medicinal herb used primarily for its bioactive phytochemical content rather than macronutrient density. Macronutrient data for isolated plant material is limited, but dried herb preparations contain approximately 10-15% protein by dry weight, 2-5% lipids, and 50-60% carbohydrates including structural polysaccharides. Key bioactive compounds are well-documented: Lignans are the primary active constituents, with phyllanthin (0.5-1.2% dry weight) and hypophyllanthin (0.3-0.8% dry weight) being the most studied hepatoprotective agents. Flavonoids including quercetin, rutin, and astragalin are present at approximately 1-3% total flavonoid content by dry weight. Ellagitannins and gallic acid derivatives (geraniin, corilagin, phyllanthusiin) are present at 2-4% dry weight and contribute to antioxidant and antiviral properties. Alkaloids including phyllantidine and phyllantine are present in trace amounts (<0.1% dry weight). Terpenes including lupeol and beta-sitosterol are present at approximately 0.1-0.5% dry weight and contribute to anti-inflammatory activity. Regarding micronutrients: vitamin C has been measured at 170-200 mg per 100g fresh weight in whole plant material; potassium is present at approximately 200-300 mg per 100g; calcium at 80-120 mg per 100g; and iron at 3-5 mg per 100g. Dietary fiber content is estimated at 15-20% dry weight. Bioavailability notes: Phyllanthin and hypophyllanthin demonstrate moderate oral bioavailability with lipophilic character suggesting improved absorption with fat-containing meals. Tannins present may reduce iron and protein bioavailability when consumed in high quantities. Aqueous extracts show higher flavonoid bioavailability compared to raw plant material. Standardized extracts are typically normalized to phyllanthin content (minimum 0.3-1% phyllanthin) for therapeutic preparations.
Reported Mechanism (Provisional)
Bhumi Amla's hepatoprotective effects are primarily attributed to lignans like phyllanthin and hypophyllanthin, which modulate cytochrome P450 enzymes and inhibit HBsAg production in vitro. Its nephroprotective action involves inhibiting calcium oxalate crystal aggregation and promoting the excretion of stone-inhibiting compounds like magnesium and potassium. Preliminary evidence suggests it may also influence glucose metabolism via alpha-glucosidase inhibition.
Clinical Narrative (Provisional)
Clinical evidence for Bhumi Amla is largely based on traditional use and preclinical studies. While animal models and in vitro studies suggest hepatoprotective effects via lignans and potential anti-diabetic activity, robust human clinical trials are scarce. For kidney stones, a few small human studies indicate it may help prevent recurrence, but larger, well-controlled trials are needed to confirm efficacy and establish optimal dosages. Current data does not support definitive health claims.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.